BeyondSpring (NASDAQ:BYSI) Releases Earnings Results, Beats Estimates By $1.78 EPS

BeyondSpring (NASDAQ:BYSI) announced its quarterly earnings data on Friday. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $1.78, FiscalAI reports.

BeyondSpring Stock Performance

NASDAQ:BYSI traded up $0.00 during mid-day trading on Friday, hitting $0.60. The company had a trading volume of 33,174 shares, compared to its average volume of 278,819. The business’s fifty day moving average is $0.66 and its two-hundred day moving average is $1.23. BeyondSpring has a fifty-two week low of $0.42 and a fifty-two week high of $2.44. The firm has a market cap of $24.72 million, a P/E ratio of -5.01 and a beta of -0.12.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, BeyondSpring presently has an average rating of “Sell”.

About BeyondSpring

BeyondSpring Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s lead product candidate is plinabulin, a small-molecule agent designed to provide both anticancer and immune-modulating effects. Plinabulin has been investigated as a treatment to prevent chemotherapy-induced neutropenia, a potentially serious reduction in infection-fighting white blood cells that can occur during cancer treatment.